RS Research is a clinical-stage biotechnology start-up developing next generation nanomedicines based on innovative drug delivery platform Sagitta® for targeted chemotherapy.
The company has 5 drug candidates, with different indications in oncology. The most advanced one has completed pre-clinical phase and started Phase-I clinical trial in NSCLC.
Following its 2 million EUR seed investment in 2017, RS Research announced the closing of Series-A investment round worth 12 million USD in December 2021.
Location: Turkey, Marmara Region, Istanbul
Member count: 11-50
Total raised: $1.179808M
Founded date: 2015
Investors 1
| Date | Name | Website |
| 28.03.2023 | ACT Ventur... | act-vc.com |
Funding Rounds 1
| Date | Series | Amount | Investors | Deal News |
| 21.04.2017 | - | $1.179808M | - | finsmes.co... |
Mentions in press and media 1
| Date | Title | Description | Category | Author | Source |
| 21.04.2017 | RS Researc... | RS Research, a Teknopark Istan... | Turkey | - | finsmes.co... |